Walz D T, Griswold D E, DiMartino M J, Bumbier E E
J Rheumatol Suppl. 1979;5:56-60.
After oral administration of auranofin (SK&F D-39162), a new antiarthritic gold compound, to rats, dogs and humans, a major portion (approximately 50%) of the blood gold content was found to be associated with cellular components. This property is in marked contrast to that reported for gold sodium thiomalate and represents another of the many physical, chemical and pharmacological differences between these therapeutic gold compounds. Although the clinical significance of this property is not presently known, it is recommended that pharmacokinetic studies involving auranofin include the assessment of both blood and serum gold levels.
在给大鼠、狗和人类口服一种新型抗关节炎金化合物金诺芬(SK&F D - 39162)后,发现血液中金含量的主要部分(约50%)与细胞成分相关。这一特性与硫代苹果酸金钠所报道的特性形成显著对比,并且代表了这些治疗性金化合物在许多物理、化学和药理学方面差异中的又一个差异。尽管目前尚不清楚这一特性的临床意义,但建议涉及金诺芬的药代动力学研究包括对血液和血清金水平的评估。